南模生物股价跌5.05%，融通基金旗下1只基金位居十大流通股东，持有80万股浮亏损失200万元

Group 1 - The core point of the news is that Nanmo Biological experienced a decline of 5.05% in its stock price, reaching 47.00 yuan per share, with a trading volume of 59.08 million yuan and a turnover rate of 1.56%, resulting in a total market capitalization of 3.664 billion yuan [1] - Nanmo Biological, established on September 20, 2000, and listed on December 28, 2021, specializes in the research, production, and sales of genetically modified animal models and related technical services [1] - The revenue composition of Nanmo Biological includes standardized models (48.34%), model technical services (21.92%), model breeding (19.50%), customized models (9.34%), and other supplementary services (0.91%) [1] Group 2 - Among the top ten circulating shareholders of Nanmo Biological, a fund under Rongtong Fund holds a position, having reduced its holdings by 150,000 shares in the second quarter, now holding 800,000 shares, which accounts for 1.03% of the circulating shares [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund (000727) was established on December 25, 2014, with a latest scale of 1.816 billion yuan, achieving a year-to-date return of 16.1% and a one-year return of 12.65% [2] - The fund manager, Wan Minyuan, has a tenure of 9 years and 65 days, with the fund's total asset size at 5.957 billion yuan, achieving a best return of 146.05% and a worst return of -20.75% during his tenure [3]